LL-37 studies
2,834 journal papers mention LL-37 in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether LL-37 is safe, effective or approved for any use.
- Papers
- 2,834
- 2,650 articles, 184 reviews
- Earliest paper
- 1996
- Most papers in 2026 (198)
- Open access
- 66%
- free to read somewhere
- Reviews
- 6%
- of all papers listed
What kind of studies
Of 2,545 papers in PubMed that mention LL-37 in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials37
- Other clinical trials22
- Meta-analyses and systematic reviews7
- Other reviews263
- Case reports11
- Animal studies only172
- Studies in humans1,835
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Papers per year
1997 to 2026, peak 198 papers in a year. The latest year may still be incomplete.
Where it is published
- Journal of Investigative Dermatology86 papers
- PLoS ONE77 papers
- International Journal of Molecular Sciences52 papers
- Frontiers in Immunology51 papers
- The Journal of Immunology49 papers
The papers
Most citedName in the title
- LL-37, the only human member of the cathelicidin family of antimicrobial peptides
U. Dürr, U. S. Sudheendra, Ayyalusamy Ramamoorthy · Biochimica et Biophysica Acta (BBA) - Biomembranes · 2006
ReviewOpen access1,049 citationsRead the open copy →
- A comprehensive summary of LL-37, the factotum human cathelicidin peptide
Dieter Vandamme, Bart Landuyt, Walter H. M. L. Luyten et al. · Cellular Immunology · 2012
Review567 citations
- Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease
Joanne Michelle Kahlenberg, Mariana J. Kaplan · The Journal of Immunology · 2013
ReviewOpen access428 citationsRead the open copy →
- Impact of LL-37 on anti-infective immunity
Dawn M. E. Bowdish, Donald J. Davidson, Y. Elaine Lau et al. · Journal of Leukocyte Biology · 2004
Review374 citations
- The roles of cathelicidin LL-37 in immune defences and novel clinical applications
Anastasia Nijnik, Robert E. W. Hancock · Current Opinion in Hematology · 2008
Review288 citations
LatestName in title or abstract
- LL-37–MRGPRX2–Mast Cell Signaling in Rosacea: Current Evidence and Directions for Human Studies
Haoyang Yin, 卢益萍 · Clinical Cosmetic and Investigational Dermatology · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Inflammatory memory as a potential driver of rosacea pathogenesis: integrating mechanisms of chronic relapse and perspectives on disease modification
Ming Zhang, Zhou Zhou, 詹丹丹 et al. · Frontiers in Immunology · 2026
ReviewOpen access · CC BYRead the open copy →
- The active immune role of keratinocytes: from passive targets to key hubs in psoriatic inflammation
Yu Pei · Frontiers in Immunology · 2026
ReviewOpen access · CC BYRead the open copy →
- LL-37-based oral antimicrobial therapeutics: translational challenges and future directions—a narrative review
Jayanandan Muruganandhan, Vishnupriya Veeraraghavan, Sujatha Govindarajan · Odontology · 2026
Review
- Apoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling
Olga Evgenevna Voronko, Vitalia Sergeevna Novikova, Olesya Olegovna Klychkova et al. · International Journal of Molecular Sciences · 2026
ReviewOpen access · CC BYRead the open copy →
- Neurogenic Rosacea and Facial Dysesthesia: Neurovascular–Immune Mechanisms and Translational Therapeutic Perspectives
Serap Maden · Medicina · 2026
ReviewOpen access · CC BYRead the open copy →
Each list shows up to 40 papers.See all 2,834 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:26 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.